Clinical Research Studies
| Trials |
|---|
This research study involves the use of Magnetic Resonance Imaging (MRI) to study the effects of COVID-19 on the heart. Since COVID-19 is a new disease, we do not yet understand the different ways that it may effect the body. There is some evidence that individuals with COVID- 1… This research study involves the use of Magnetic Resonance Imaging (MRI) to study the effects of COVID-19 on the heart. Since COVID-19 is a new disease, we do not yet understand the different ways that it may effect the body. There is some evidence that individuals with COVID- 19 are at higher risk for heart complications. The purpose of this study is to use recently developed MRI techniques to compare heart health of individuals with COVID-19 to people who were asymptomatic or are healthy. The new MRI techniques used in this experiment may also allow researchers and health care providers to take clearer pictures of the heart in other individuals. |
This study aims to capture a better image of the heart using MR imaging. This enables comprehensive evaluation of the heart, including cardiac function, perfusion, edema, and scar/fibrosis. |
To develop new MRI approaches that can better quantify the severity of left atrial fibrosis, for the purposes of predicting whether patients will revert to atrial fibrillation (AF) following an initial successful procedure Primary Inclusion Criteria:
Primary Exclusion Criteria:
STU00213834 |
This is a first-in-human, Phase I, open-label, multicenter study designed to evaluate the safety, tolerability and preliminary efficacy of WTX-124, a conditionally activated IL-2 prodrug, when administered as monotherapy and in combination with pembrolizumab, for the treatment of patients with ad… This is a first-in-human, Phase I, open-label, multicenter study designed to evaluate the safety, tolerability and preliminary efficacy of WTX-124, a conditionally activated IL-2 prodrug, when administered as monotherapy and in combination with pembrolizumab, for the treatment of patients with advanced solid tumors. Part 1 of the study is dose escalation of WTX-124, both as monotherapy and in combination with pembrolizumab. Part 2 is comprised of four arms in which WTX-124 will be administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic cutaneous malignant melanoma or advanced or metastatic renal cell carcinoma.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of advanced stage or metastatic solid tumor for which anti-PD(L)-1 is indicated. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05479812 STU00218459 |
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors
Note: Thi… The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor by pathology report with oncogenically activated receptor tyrosine kinase (RTK) confirmed by a historical report or local testing and have received, or been intolerant to, all available treatment known to confer clinical benefit
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05853367 STU00219386 |
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinat… This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Some of the eligibility criteria include:
· Participants must have a diagnosis of Histopathologically or cytologically confirmed ER+, HER2-, breast cancer · At least one measurable lesion as per RECIST version 1.1 or a mainly lytic bone lesion. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete
NCT05563220 STU00219475 |
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvest… HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide. Some of the eligibility criteria include:
· Participants must have a diagnosis of HR-positive and HER2-negative breast cancer · Participants must be 18 or older
·
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05207709 STU00219690 |
Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied … Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting. The purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining it with a targeted agent such as a CDK4/6 inhibitor to treat patients with ER+/HER2- or metastatic breast cancer with prior exposure to a CDK4/6 inhibitor.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of histologically or cytologically confirmed ER-positive and HER2- negative breast cancer as per the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT06062498 STU00219978 |
This study aims to examine the use of radiotherapy and its ability to keep cancer controlled for longer than with just standard medications on their own. Patients will undergo standard systemic therapy (treatment that is widely used by healthcare professionals for your cancer), and then imaging (… This study aims to examine the use of radiotherapy and its ability to keep cancer controlled for longer than with just standard medications on their own. Patients will undergo standard systemic therapy (treatment that is widely used by healthcare professionals for your cancer), and then imaging (fluorodeoxyglucose (FDG)-positron emission tomography or FDG-PET) to identify cancer sites that remain active despite the treatment. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of prostate cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT06244004 STU00220350 |